CCP
TSVT

Clough Capital Partners’s 2seventy bio TSVT Stock Holding History

Clough Capital Partners’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-510,910
Closed -$2M – 226
2023
Q3 		$2M Sell
510,910
-18,200
-3% -$119K 0.21% 95
2023
Q2 		$5.35M Buy
529,110
+280,500
+113% +$2.97M 0.54% 60
2023
Q1 		$2.54M Buy
+248,610
New +$2.84M 0.27% 96

Other funds holding TSVT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Clough Capital Partners's TSVT Position: Q4 2023 in Review

Clough Capital Partners sold out of 2seventy bio (TSVT) in Q4 2023, closing a stake of 510,910 shares — an estimated $2M sold.

Clough Capital Partners first reported a position in TSVT in Q1 2023 and held it in 3 quarters. The position peaked at $5.35M in Q2 2023. 116 funds tracked by Wall St. Rank hold TSVT as of Q4 2023.

  • Clough Capital Partners reported no remaining 2seventy bio position as of Q4 2023 after selling out during the quarter.
  • Clough Capital Partners sold 510,910 2seventy bio shares in Q4 2023, an estimated $2M.
  • Clough Capital Partners first reported a position in 2seventy bio in Q1 2023 and held it in 3 quarters.
  • Clough Capital Partners's 2seventy bio position peaked at $5.35M in Q2 2023.
  • 116 funds tracked by Wall St. Rank held 2seventy bio as of Q4 2023.

Based on Clough Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.